

Hao Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10448890/publications.pdf>

Version: 2024-02-01

33
papers

965
citations

361388
20
h-index

434170
31
g-index

34
all docs

34
docs citations

34
times ranked

805
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolism of Benzo[<i>a</i>]pyrene in Human Bronchoalveolar H358 Cells Using Liquid Chromatography–Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2007, 20, 1331-1341.	3.3	76
2	Fully Validated LC-MS/MS Assay for the Simultaneous Quantitation of Coadministered Therapeutic Antibodies in Cynomolgus Monkey Serum. <i>Analytical Chemistry</i> , 2013, 85, 9859-9867.	6.5	74
3	Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. <i>British Journal of Pharmacology</i> , 2004, 141, 616-623.	5.4	58
4	Competing Roles of Cytochrome P450 1A1/1B1 and Aldo-Keto Reductase 1A1 in the Metabolic Activation of (±)-7,8-Dihydroxy-7,8-dihydro-benzo[<i>a</i>]pyrene in Human Bronchoalveolar Cell Extracts. <i>Chemical Research in Toxicology</i> , 2005, 18, 365-374.	3.3	56
5	Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 409-418.	2.8	56
6	Competing Roles of Aldo-Keto Reductase 1A1 and Cytochrome P4501B1 in Benzo[<i>a</i>]pyrene-7,8-diol Activation in Human Bronchoalveolar H358 Cells: A Role of AKRs in P4501B1 Induction. <i>Chemical Research in Toxicology</i> , 2006, 19, 68-78.	3.3	42
7	Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography–tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 769, 169-176.	2.3	39
8	Quantification of benzo[<i>a</i>]pyrene diol epoxide DNA-adducts by stable isotope dilution liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 1369-1380.	1.5	39
9	Practical and Efficient Strategy for Evaluating Oral Absolute Bioavailability with an Intravenous Microdose of a Stable Isotopically-Labeled Drug Using a Selected Reaction Monitoring Mass Spectrometry Assay. <i>Analytical Chemistry</i> , 2012, 84, 10031-10037.	6.5	39
10	Innovative Use of LC-MS/MS for Simultaneous Quantitation of Neutralizing Antibody, Residual Drug, and Human Immunoglobulin G in Immunogenicity Assay Development. <i>Analytical Chemistry</i> , 2014, 86, 2673-2680.	6.5	38
11	Current advances and strategies towards fully automated sample preparation for regulated LC–MS/MS bioanalysis. <i>Bioanalysis</i> , 2014, 6, 2441-2459.	1.5	36
12	Calculation and Mitigation of Isotopic Interferences in Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability Studies. <i>Analytical Chemistry</i> , 2012, 84, 4844-4850.	6.5	35
13	A sensitive and accurate liquid chromatography–tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine. <i>Journal of Chromatography A</i> , 2012, 1245, 117-121.	3.7	34
14	Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1260-1272.	2.0	32
15	2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part) Tj ETQq1 1 0.784314 rgBT /C	1.5	32
16	Benzo[<i>a</i>]pyrene-7,8-dihydrodiol Promotes Checkpoint Activation and G2/M Arrest in Human Bronchoalveolar Carcinoma H358 Cells. <i>Molecular Pharmacology</i> , 2007, 71, 744-750.	2.3	30
17	Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. <i>Drug Metabolism and Disposition</i> , 2016, 44, 238-249.	3.3	28
18	A Convenient Strategy for Quantitative Determination of Drug Concentrations in Tissue Homogenates Using a Liquid Chromatography/Tandem Mass Spectrometry Assay for Plasma Samples. <i>Analytical Chemistry</i> , 2011, 83, 6237-6244.	6.5	23

#	ARTICLE	IF	CITATIONS
19	An exploratory universal LC-MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies. <i>Bioanalysis</i> , 2014, 6, 1747-1758.	1.5	23
20	Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. <i>Journal of Immunological Methods</i> , 2015, 416, 94-104.	1.4	23
21	A User-Friendly Robotic Sample Preparation Program for Fully Automated Biological Sample Pipetting and Dilution to Benefit the Regulated Bioanalysis. <i>Journal of the Association for Laboratory Automation</i> , 2012, 17, 211-221.	2.8	20
22	Development and validation of an LC-MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. <i>Bioanalysis</i> , 2014, 6, 2371-2383.	1.5	19
23	A validated LC-MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 973, 1-8.	2.3	19
24	Sensitivity-based analytical approaches to support human absolute bioavailability studies. <i>Bioanalysis</i> , 2014, 6, 497-504.	1.5	19
25	A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 921-922, 81-86.	2.3	16
26	A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2064-2072.	2.3	14
27	Characterization of ADME properties of [¹⁴ C]asunaprevir (BMS-650032) in humans. <i>Xenobiotica</i> , 2016, 46, 52-64.	1.1	13
28	Overcoming interference with the detection of a stable isotopically labeled microtracer in the evaluation of beclabuvir absolute bioavailability using a concomitant microtracer approach. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 9-16.	2.8	8
29	A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 119, 145-151.	2.8	6
30	Perspectives on exploring hybrid LBA/LC-MS approach for clinical immunogenicity testing. <i>Bioanalysis</i> , 2019, 11, 1605-1617.	1.5	6
31	Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 17-23.	2.8	5
32	Concerted application of LC-MS and ligand binding assays to better understand exposure of a large molecule drug. <i>Bioanalysis</i> , 2018, 10, 1261-1272.	1.5	3
33	Choosing the right bioanalytical assay platform(s) to support the PK assessment of protein biotherapeutic programs. <i>Bioanalysis</i> , 2015, 7, 1197-1199.	1.5	2